Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01171391 · ClinicalTrials.gov registry record · Phase 1
VA106483 Dose Response in Females
A Phase 1 study, sponsored by Vantia.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01171391: Completed Phase 1 study, sponsored by Vantia.
NCT01171391 is a Phase 1 study that has completed, run by Vantia. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01171391, a Phase 1 study, has completed, sponsored by Vantia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to describe the pharmacokinetics and pharmacodynamics of VA106483 in female subjects.
Primary Outcome
VA106483 plasma concentration pre-dose over a 24hr post-dose period to assess pharmacokinetics of each dose level
Interventions
- OTHER Placebo
- DRUG VA106483
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-07 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
What the finished NCT01171391 record still lists
NCT01171391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01171391 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01171391 about?
NCT01171391 is a clinical study titled "VA106483 Dose Response in Females". The purpose of this study is to describe the pharmacokinetics and pharmacodynamics of VA106483 in female subjects.
What is the current status of trial NCT01171391?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2010-07. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01171391?
The interventions under investigation include: Placebo (OTHER), VA106483 (DRUG).
Who is sponsoring clinical trial NCT01171391?
This trial is sponsored by Vantia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01171391's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia